Dennis Schmatz joins Scynexis
Will provide advice to US firm as it advances drug development programme
Scynexis president and chief executive Dr Yves Ribeill, said: ‘His contributions to Scynexis will be important as we aggressively pursue the development of our cyclophilin inhibitor technology platform and the discovery of global health therapeutics for neglected diseases.’
Schmatz was most recently interim president and chief executive of the Medicines for Malaria Venture, a non-profit foundation in Geneva, Switzerland created to discover anti-malarial drugs through public-private partnerships. Previously he was vice president of Merck Research Laboratories USA and head of the Tsukuba Research Institute of Banyu Research Laboratories in Japan.
‘It's an exciting time to be joining the Scynexis team as both their HCV compounds, SCY-635, and their partnered broad-spectrum antifungal compound, MK-3118, advance through clinical development,’ Schmatz said. ‘I see a promising future for Scynexis and am honoured to be a part of it.’
You may also like
Research & Development
Scientists develop new technique to fight antimicrobial resistance
The team of researchers from the University of Leicester have developed a new technique to sequence phage genomes from individual plaques and hopes to use it to build fully characterised libraries of bacteriophages, expanding the number of candidates available to tackle drug-resistant infections
Research & Development
Lancet Oncology Commission launches to examine future of academic cancer clinical trials amid funding and regulatory pressures
A global coalition of clinical investigators and patient representatives has launched the Lancet Oncology Commission to address the value and challenges of independent academic cancer clinical trials, amid growing concerns over regulatory complexity, limited public funding and the need for new international collaboration models
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
UK clinical trial reforms come into force in largest regulatory overhaul in 20 years
The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Research & Development
Epitopea receives MHRA approval for first-in-human trial of RNA vaccine for ovarian cancer
The company has received regulatory approval from the MHRA and Regional Ethics Committee to initiate its OVACT Phase I/Ib clinical trial of CryptiVax-1001, an off-the-shelf mRNA immunotherapy targeting high-grade serous ovarian cancer
Research & Development
NEUVIOR Pharmaceuticals receives Innovate UK grant to explore bio-based materials for circular pharmaceutical manufacturing
The Innovate UK feasibility grant will advance its ZYLON programme, which involves clean-chemistry lab trials exploring how bio-derived materials could replace harder-to-recycle packaging formats and reduce waste in pharmaceutical manufacturing